Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • View or Listen to JNM Podcast
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Follow JNM on Twitter
  • Subscribe to our RSS feeds
Meeting ReportOncology-Clinical Diagnosis: Solid Tumors

The role of the change of tumor metabolic volume (MV) for monitoring cancer therapy in 18F-FDG-PET/CT

Shigeki Nagamachi, Shogo Kiyohara, Hideyuki Wakamatsu, Seigo Fujita, Shigemi Futami, Shozo Tamura and Hideo Arita
Journal of Nuclear Medicine May 2008, 49 (supplement 1) 371P;
Shigeki Nagamachi
1Radiology, Miyazaki Medical College, Miyazaki-gun, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Shogo Kiyohara
1Radiology, Miyazaki Medical College, Miyazaki-gun, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hideyuki Wakamatsu
1Radiology, Miyazaki Medical College, Miyazaki-gun, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Seigo Fujita
1Radiology, Miyazaki Medical College, Miyazaki-gun, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Shigemi Futami
1Radiology, Miyazaki Medical College, Miyazaki-gun, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Shozo Tamura
1Radiology, Miyazaki Medical College, Miyazaki-gun, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hideo Arita
1Radiology, Miyazaki Medical College, Miyazaki-gun, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
Loading

Abstract

1568

Objectives: We performed the current study to investigate the usefulness of MV in monitoring therapeutic effects in various cancers.

Methods: We evaluated the serial change of maximum SUV (SUVmax) and metabolic volume (MV) obtained by 18F-FDG-PET/CT performed in forty-five patients with various cancer. The patients include 14 lung cancers, 12 malignant lymphomas, 7 colon cancer, 5 esophageal cancers and 7 other cancers. The value of MV was calculated in condition at 50% cutoffs. Both SUVmax and MV were obtained before and after cancer therapy. We evaluated the correlation between SUVmax and MV. We also evaluated the correlation of % change of both indices, calculated as (index obtained at post-therapy / index obtained at pre-therapy).

Results: The value of SUVmax weakly correlated positively with that of MV (r=0.52). In contrast, the correlation between %change of both index was fairly good (r=0.73).

Conclusions: The serial change of tumor metabolic volume correlates with that of SUVmax. The tumor metabolic volume obtained by 18F-FDG-PET/CT , %change in particular, is useful index for monitoring the therapeutic effects in cancer therapy.

  • Society of Nuclear Medicine, Inc.
Back to top

In this issue

Journal of Nuclear Medicine
Vol. 49, Issue supplement 1
May 1, 2008
  • Table of Contents
  • Index by author
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
The role of the change of tumor metabolic volume (MV) for monitoring cancer therapy in 18F-FDG-PET/CT
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
The role of the change of tumor metabolic volume (MV) for monitoring cancer therapy in 18F-FDG-PET/CT
Shigeki Nagamachi, Shogo Kiyohara, Hideyuki Wakamatsu, Seigo Fujita, Shigemi Futami, Shozo Tamura, Hideo Arita
Journal of Nuclear Medicine May 2008, 49 (supplement 1) 371P;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
The role of the change of tumor metabolic volume (MV) for monitoring cancer therapy in 18F-FDG-PET/CT
Shigeki Nagamachi, Shogo Kiyohara, Hideyuki Wakamatsu, Seigo Fujita, Shigemi Futami, Shozo Tamura, Hideo Arita
Journal of Nuclear Medicine May 2008, 49 (supplement 1) 371P;
Twitter logo Facebook logo LinkedIn logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
  • Info & Metrics

Related Articles

  • No related articles found.
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

Oncology-Clinical Diagnosis: Solid Tumors

  • Results of 18F-FDG PET/CT and 68Ga-DOTA-TOC PET/CT correlate with tissue markers of poor prognosis in neuroendocrine tumors
  • F-18 FDG uptake of pulmonary lymphangitic carcinomatosis according to the interstitial involvement patterns in the lung cancer patients
  • Dual-time point F-18 FDG PET/CT for the differentiation of malignant and benign bone lesions
Show more Oncology-Clinical Diagnosis: Solid Tumors

Clinical Diagnosis-Solid Tumors Posters

  • The value of F-18 FDG PET/CT in the detection of recurrent colorectal cancer: Comparison with serum CEA level
  • Efficacy of PET/CT for colorectal cancer screening
  • F-18 FDG uptake of pulmonary lymphangitic carcinomatosis according to the interstitial involvement patterns in the lung cancer patients
Show more Clinical Diagnosis-Solid Tumors Posters

Similar Articles

SNMMI

© 2025 SNMMI

Powered by HighWire